AU4239302A - Benzoic acid substituted benzopyrans for the treatment of atherosclerosis - Google Patents

Benzoic acid substituted benzopyrans for the treatment of atherosclerosis Download PDF

Info

Publication number
AU4239302A
AU4239302A AU42393/02A AU4239302A AU4239302A AU 4239302 A AU4239302 A AU 4239302A AU 42393/02 A AU42393/02 A AU 42393/02A AU 4239302 A AU4239302 A AU 4239302A AU 4239302 A AU4239302 A AU 4239302A
Authority
AU
Australia
Prior art keywords
alkyl
phenyl
compound
optionally substituted
ltb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU42393/02A
Other languages
English (en)
Inventor
Robert Joseph Aiello
Patricia-Ann Bourassa
Saralyn Lindsey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU4239302A publication Critical patent/AU4239302A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU42393/02A 2001-06-28 2002-05-20 Benzoic acid substituted benzopyrans for the treatment of atherosclerosis Abandoned AU4239302A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30171201P 2001-06-28 2001-06-28
US60301712 2001-06-28
US32825401P 2001-10-10 2001-10-10
US60328254 2001-10-10

Publications (1)

Publication Number Publication Date
AU4239302A true AU4239302A (en) 2003-01-02

Family

ID=26972559

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42393/02A Abandoned AU4239302A (en) 2001-06-28 2002-05-20 Benzoic acid substituted benzopyrans for the treatment of atherosclerosis

Country Status (12)

Country Link
EP (1) EP1270000A3 (enExample)
JP (1) JP2003034638A (enExample)
KR (1) KR20030015828A (enExample)
CN (1) CN1394602A (enExample)
AU (1) AU4239302A (enExample)
CA (1) CA2391205A1 (enExample)
CZ (1) CZ20022076A3 (enExample)
HK (1) HK1049795A1 (enExample)
HU (1) HUP0202114A3 (enExample)
IL (1) IL150340A0 (enExample)
PL (1) PL354770A1 (enExample)
SK (1) SK8682002A3 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4476934B2 (ja) * 2003-04-14 2010-06-09 明治乳業株式会社 新規ペプチドおよび免疫賦活剤、機能性食品ならびに機能性食品の製造方法
KR20070035101A (ko) * 2004-07-22 2007-03-29 파마시아 코포레이션 Ｃｏｘ-2 선택적 억제제 및 ｌｔｂ4 수용체 길항제의조합을 이용한 염증 및 통증 치료 조성물
JP5846711B2 (ja) * 2005-06-09 2016-01-20 メダ アーベー 炎症性疾患の治療のための方法及び組成物
US10336733B2 (en) 2015-11-30 2019-07-02 Merk Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
EP3383389B1 (en) 2015-11-30 2021-04-28 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720493A1 (de) * 1987-06-20 1989-01-26 Nattermann A & Cie Arzneizubereitungen mit mikronisierten ebselen-kristallen
MX9300312A (es) * 1992-01-23 1993-07-31 Pfizer Antagonistas benzopiranicos y relacionado de ltb.
DE4228200A1 (de) * 1992-08-25 1994-03-03 Schering Ag Neue Pyridin-Derivate mit Leukotrien-B¶4¶-antagonistischer Wirkung
CN1160399A (zh) * 1994-10-13 1997-09-24 美国辉瑞有限公司 苯并吡喃和苯并稠合化合物、其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途
KR100232340B1 (ko) * 1994-10-13 1999-12-01 디. 제이. 우드, 스피겔 알렌 제이 류코트리엔 b4(ltb4) 길항물질로서의 벤조피란 및 벤조-축합된 화합물
CA2224563A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
DE19636689A1 (de) * 1996-09-10 1998-03-12 Boehringer Ingelheim Kg Neue Benzamidinderivate
JP3117730B2 (ja) * 1996-09-16 2000-12-18 ファイザー・インク 置換クロマール誘導体を製造するための方法及び中間体
EP0963755A3 (en) * 1998-04-16 2001-03-14 Pfizer Products Inc. Use of benzopyranes for preventing allograft rejection
AU5687199A (en) * 1998-08-24 2000-03-14 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
JP2003225088A (ja) * 1999-09-10 2003-08-12 Meiji Seika Kaisha Ltd ヒト・ロイコトリエンｂ４第二受容体及びそれをコードするｄｎａ
EP1268777A2 (en) * 2000-03-17 2003-01-02 Bayer Aktiengesellschaft Regulation of human leukotriene b 4?-like g protein-coupled receptor

Also Published As

Publication number Publication date
HU0202114D0 (enExample) 2002-09-28
CN1394602A (zh) 2003-02-05
CZ20022076A3 (cs) 2004-05-12
HK1049795A1 (zh) 2003-05-30
HUP0202114A2 (hu) 2003-01-28
KR20030015828A (ko) 2003-02-25
SK8682002A3 (en) 2004-08-03
PL354770A1 (en) 2002-12-30
EP1270000A2 (en) 2003-01-02
EP1270000A3 (en) 2003-02-12
JP2003034638A (ja) 2003-02-07
IL150340A0 (en) 2002-12-01
HUP0202114A3 (en) 2004-07-28
CA2391205A1 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
CA2221114C (en) Atherosclerosis treatment
JP2023184606A (ja) 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法
EP1176134A1 (en) Ligands of nuclear receptors ppar's
JP2012523459A (ja) 炎症を処置するための組成物及び方法
EP1469842A2 (en) Bicyclic cb2 cannabinoid receptor ligands
JP2019031495A (ja) 選択的ｍａｏ−ｂ阻害剤化合物、その医薬組成物及びその使用
WO2014090990A1 (en) Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease
WO2003064359A1 (en) Bicyclic cb2 cannabinoid receptor ligands
EP1485083A2 (en) Dexanabinol and dexanabinol analogs regulate inflammation related genes
AU2003209616B2 (en) Bicyclic CB2 cannabinoid receptor ligands
EP1270000A2 (en) Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
AU2003209616A1 (en) Bicyclic CB2 cannabinoid receptor ligands
US20050137251A1 (en) Dexanabinol and dexanabinol analogs regulate inflammation related genes
CN102428078A (zh) 神经保护、降胆固醇以及抗癫痫的化合物
CS273610B2 (en) Method of silibinene's new derivatives production
WO1995015957A1 (en) Chroman derivative
EP4735422A1 (en) Substituted cyclic compounds and methods of treating phenylketonuria and other amino acidurias
JP5478082B2 (ja) インターロイキン−２産生抑制剤
EP3179998B1 (en) Compounds for the treatment of hpv-induced carcinoma
EP0337885B1 (fr) Nouveaux dérivés triéniques de structure chroménique, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
US4883813A (en) Method of treating inflammation in mammals utilizing ketobutyrolactones and furylbutyrolactones
JP7787382B2 (ja) カンナビジオール誘導体、その調製方法及び使用
JP2009023935A (ja) 消炎剤、関節炎における炎症性疾患治療剤
JPS62132879A (ja) ３，４−ジヒドロ−２ｈ−ベンゾピラン誘導体類及びこれを有効成分とする抗アレルギ−剤
JP2001316260A (ja) カバラクトン類を有効成分とするＴＮＦ−α産生抑制剤